Want to see KPRX full AI Analyst Report?
Kio-104
Macular Edema
Phase II
Recruiting
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Feb 04, 2025
―
100 Μg Kio-301, 50 Μg Kio-301
Retinitis Pigmentosa
Phase II
Recruiting
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Oct 03, 2024
―
Kio-301
Retinitis Pigmentosa, Choroideremia
Phase I/II
Recruiting
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Mar 08, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Kiora Pharmaceuticals (KPRX) have in its pipeline
KPRX is currently developing the following drugs: Kio-104, 100 Μg Kio-301, 50 Μg Kio-301, Kio-301. These drug candidates are in various stages of clinical development as the company works toward FDA approval.